ASTRIX HEALTH LIMITED


Directors	BLAKE, Thomas
	SWAMINATHAN, Abhinav


Registered Address	Arquen House
	4-6 Spicer Street
	St. Albans
	AL3 4PQ


Registered Number	16008940 (England and Wales)

Balance Sheet as at
5 May 2026

	Notes	05 May 2026		31 Dec 2025
		£	£	£	£
Current assets
Debtors	4	-		843
Cash at bank and on hand		102		711
		102		1,554
Creditors amounts falling due within one year	5	(109)		-
Net current assets (liabilities)			(7)		1,554
Total assets less current liabilities			(7)		1,554
Creditors amounts falling due after one year	6		-		(9,330)
Net assets			(7)		(7,776)
Capital and reserves
Profit and loss account			(7)		(7,776)
Shareholders' funds			(7)		(7,776)

The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company’s profit and loss account under section 444 (5A) Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 3 July 2026, and are signed on its behalf by:

BLAKE, Thomas
Director
Registered Company No. 16008940

ASTRIX HEALTH LIMITED

Notes to the Financial Statements
for the period ended 5 May 2026

1.	Accounting policies

	Statutory information
	The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

	Statement of compliance
	The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

	Functional and presentation currency
	The financial statements are presented in sterling and this is the functional currency of the company.

	Going concern
	During the period, the Directors resolved to apply for voluntary strike-off of the Company. The Company has ceased trading activities and intends to settle outstanding balances prior to dissolution. Consequently, the directors do not consider the going concern basis of accounting to be appropriate.These financial statements have therefore been prepared on a break-up basis. Assets have been stated at their estimated realisable values and liabilities at the amounts expected to be settled.

Going concern

During the period, the Directors resolved to apply for voluntary strike-off of the Company. The Company has ceased trading activities and intends to settle outstanding balances prior to dissolution.

Consequently, the directors do not consider the going concern basis of accounting to be appropriate.These financial statements have therefore been prepared on a break-up basis. Assets have been stated at their estimated realisable values and liabilities at the amounts expected to be settled.

	Judgements and key sources of estimation uncertainty
	In preparing the financial statements on a break-up basis, the directors have exercised judgement in estimating the realisable value of assets and settled value of liabilities.

	Turnover policy
	Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the rendering of services.

	Foreign currency translation
	Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

Foreign currency translation

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

	Current taxation
	Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

2.	Average number of employees


		2026		2025
	Average number of employees during the year	0		1

3.	Further information regarding the company's income
	These financial statements have been prepared for the period from 1 January 2026 to 5 May 2026. This represents the Company's final set of financial statements before dissolution. The comparative figures represent the financial statements in the prior period covering 9 October 2024 to 31 December 2025.

4.	Debtors: amounts due within one year

	2026	2025
	£	£
Other debtors	-	843
Total	-	843

5.	Creditors: amounts due within one year

	2026	2025
	£	£
Trade creditors / trade payables	109	-
Total	109	-

6.	Creditors: amounts due after one year

	2026	2025
	£	£
Amounts owed to related parties	-	9,330
Total	-	9,330

7.	Related party transactions
	During the period, on 5 May 2026, the balance owed by the Company of £9,702 to its parent undertaking, Astrix Health Inc, based in the United States was waived in full. During the period, the Company provided software development services to its parent undertaking, Astrix Health Inc, based in the United States. Fees of £nil (2025: £61,521) were charged in accordance with the Group's transfer pricing policy and are considered to be at arm's length.

Related party transactions

During the period, on 5 May 2026, the balance owed by the Company of £9,702 to its parent undertaking, Astrix Health Inc, based in the United States was waived in full.

During the period, the Company provided software development services to its parent undertaking, Astrix Health Inc, based in the United States. Fees of £nil (2025: £61,521) were charged in accordance with the Group's transfer pricing policy and are considered to be at arm's length.